PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats

Adrienne Brouwers, Iris Verel, Julliëtte Van Eerd, Gerard Visser, Martijn Steffens, Egbert Oosterwijk, Frans Corstens, Wim Oyen, Guus Van Dongen, Otto Boerman*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Introduction: With the introduction of positron-emitting radionuclides with half-lifes in days, such as 89Zr and 124I, radioimmunoscintigraphy (RIS) with positron-emitter-labeled monoclonal antibodies (moAbs) becomes feasible. RIS, using positron emission tomography (immuno-PET), combines the specific localization of an antibody with the high resolution of a PET camera. In the present study, scintigraphic tumor imaging using chimeric moAb G250 labeled with 89Zr (immuno-PET) or 111In (RIS), and [18F]FDG-(PET) was explored in rats with s.c. renal cell carcinoma (RCC) tumors. Methods: Nude rats (6-8 rats per group) with s.c. SK-RC-52 tumors were i.v. injected with 4 MBq 111In-DTPA-cG250, 20 MBq 89Zr-Df-cG250 or 4 MBq [ 18F]FDG. Planar 111In-DTPA-cG250 images were obtained 5 minutes, and 24, 48, and 72 hours postinjection (p.i.). 3D PET imaging was performed 5 minutes, and 24, 48, and 72 hours after a 89Zr-Df-cG250 injection and 1 hour after a [18F]FDG injection using a Siemens ECAT EXACT PET camera. Rats were killed after the last imaging session, and the uptake of the radiolabel in the dissected tissues was determined. Results: Both radiolabeled antibody preparations were stable during 4 days of incubation in serum at 37°C, and the immunoreactivity was preserved. Two (2) days after injection, s.c. tumors (100 mg) were clearly visualized, both with 89Zr-Df-cG250 and 111In-DTPA-cG250. Tumors were not visualized with [18F]FDG (uptake in tumor of 0.5 ± 0. 1%ID/G, 1 hour p.i.). The biodistribution experiments showed an identical uptake in the tumor for both 89Zr-Df-cG250 and 111In-DTPA-cG250 at 3 days p.i. (5.0 ± 2.4 and 4.9 ± 2.9 %ID/g, respectively). Blood levels at 3 days p.i. were also identical (1.4 ± 0.4 versus 1.7 ± 0.7 %ID/g), and no significant differences were found in the biodistribution of normal tissues between the two radiolabeled cG250 preparations. Conclusion: The cG250 antibody can be stably labeled with the positron-emitter 89Zr, while preserving the immunoreactivity of the moAb. In this rat model, the in vivo biodistribution of 89Zr-Df-cG250 was identical to that of 111In-DTPA-cG250. Immuno-PET of RCC is feasible with 89Zr-cG250, and relatively small tumors could be visualized, even without a dedicated PET camera for small animals.

Original languageEnglish
Pages (from-to)155-163
Number of pages9
JournalCancer Biotherapy and Radiopharmaceuticals
Issue number2
Publication statusPublished - 8 Jun 2004

Cite this